Demonstrate an understanding of the global economics underlying fleet planning according to the market, constraints and the airline’s need.
Outcome 3: Compute data in order to successfully carry out fleet planning analysis.
Outcome 4: Make appropriate recommendations of a fleet type for a particular market
You are working in the Fleet Planning Department of an airline. Your airline is planning to launch a new route to a destination it is not currently serving. You have been tasked with writing a business report to senior management that will
(1) identify a suitable destination and the appropriate aircraft and capacity to serve it
(2) identify and calculate key economic parameters to analyse the feasibility of the route
(3) make a conclusion for a go or no-go decision and recommendation on whether or not to launch, based on your analysis in (1) and (2) above and
(4) write a personal learning paper on your experience and learnings from this assignment and the overall module.
- Airline and route selection, demand and revenue forecasts and aircraft allocation
• Choose an airline that you are familiar with and/or has a complete set of information easily available for research e.g. annual reports, fleet configuration etc. You can choose either a network/full service carrier or an LCC but your choice of route/destination/aircraft must be compatible with the airline’s stated strategy.
• Choose a destination that is not currently served by your airline but has potential.
• Choose an aircraft: this can be a type that your airline currently operates or will start operating within the near future or it can be an entirely new type if you have nothing suitable already in your fleet plan.
device for short amounts of time when bathing. The only downside to this treatment is that in order to use this treatment, one must shave their hair. TTF therapy is often used in combination with the chemotherapeutic drug temozolomide, sometimes abbreviated TMZ. The least common side effects, seen in 10% or less of patients, of the treatment when in combination with temozolomide are “low blood platelet count, nausea, constipation, vomiting, fatigue, scalp irritation from device use, headache, convulsions, and depression”. The most common side effects of just using TTF are “scalp irritation from device use and headache”. There are also adverse reactions seen in relation to using the device such as “scalp irritation from device use, headache, malaise, muscle twitching, fall and skin ulcer” (Novocure). The cost of TTF therapy, specifically Optune, runs at $21,000 a month. On average, patients use TTF therapy for 4.1 months and so the cost falls around $86,000. According to the Emerging Technology Evidence Report, currently, Medicare does not have a determination on the national coverage of TTF therapy, so it is up to the discretion of local Medicare carriers. Also, according to the report, out of eleven private insurance companies in the United States, one covers TTF therapy, seven deny coverage and consider the treatment “investigational”, and three have no policy about it. According to Novocure, the company that owns the device, many insurance companies have provided coverage of the therapy by using a case-by-case system, determined by the medical necessity of treatment. The Musella Foundation for Brain Tumor Research and Information created an assistance program from patients needing TTF therapy for recurrent GBM. Also, certain patients who live in the United States and meet specific income conditions can receive up to $5,000 per year for the treatment (ECRI Institute 2016). According to the New York Times, Novocure offers the treatment for free for patients without health coverage (Grady 2014). Prognosis When patients used Optune (TTF therapy) for 12 hours or more a day and also took TMZ during the same period, 86% of patients increased their survival rate compared to just taking TMZ alone. The more compliant patients were with using the device, the better their outcome was. In order to get the best results and maximal survival benefit, patients should aim to use the device for at least 18 hours a day. For patients who had compliance over 90%, their median survival was 24.9 months and their 5-year survival rate was 29.3% (Ram 2017). When dealing with glioblastoma (GBM), the median overall survival rate is around 15 months and the rate of 5-year survival is estimated to be 5%>GET ANSWER